SOPHiA GENETICS (SOPH) CEO awarded 628,743 options and 431,211 RSUs

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported equity compensation grants on April 2, 2026. He received 628,743 share options with an exercise price of $5.040 per ordinary share, expiring on April 2, 2036. He also received 431,211 restricted stock units (RSUs), each representing one ordinary share.

The RSUs vest with 25% on April 2, 2027, and the remaining 75% in equal quarterly installments through April 2, 2030, contingent on continued service. The options vest as to 25% on April 2, 2027, with the balance vesting in equal monthly installments through April 2, 2030. These are compensation-related awards, not open-market trades.

Insights

Equity compensation analyst

CEO received sizable option and RSU grants as routine equity compensation, not open-market buying.

The filing shows grant/award acquisitions to SOPHiA GENETICS CEO Jurgi Camblong: 628,743 options at an exercise price of $5.040 and 431,211 RSUs, all at a reported transaction price of $0.0000 because these are compensation grants.

Both awards vest over time: RSUs from April 2, 2027 through April 2, 2030 in quarterly installments, and options on the same initial date, then monthly through April 2, 2030, expiring in 2036. This structure is typical for long-term incentives and does not reflect discretionary market purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Camblong Jurgi

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	628,743	$0.00	--
Grant/Award	Ordinary Shares	431,211	$0.00	--

Holdings After Transaction: Share Option (Right to Buy) — 628,743 shares (Direct); Ordinary Shares — 431,211 shares (Direct)

Footnotes (1)

1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

Key Figures

Option grant size: 628,743 options Option exercise price: $5.040 per share Option expiration: April 2, 2036 +4 more

7 metrics

Option grant size 628,743 options Share Option (Right to Buy) granted April 2, 2026

Option exercise price $5.040 per share Exercise price for CEO share options

Option expiration April 2, 2036 Expiration date of share options

RSU grant size 431,211 RSUs Restricted stock unit grant April 2, 2026

Initial RSU vesting 25% on April 2, 2027 First RSU vesting tranche

Remaining RSU vesting 75% through April 2, 2030 Quarterly vesting installments after initial cliff

Option vesting schedule 25% on April 2, 2027 Then equal monthly installments through April 2, 2030

Key Terms

restricted stock unit ("RSU"), 2021 Equity Incentive Plan, vesting, share option vests and becomes exercisable, +1 more

5 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."

2021 Equity Incentive Plan financial

"RSU grant made under the Issuer's 2021 Equity Incentive Plan."

vesting financial

"25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

share option vests and becomes exercisable financial

"The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027."

exercise price financial

"conversion_or_exercise_price": "5.0400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Camblong Jurgi

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/02/2026		A		431,211(1)	A	$0	431,211	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$5.04	04/02/2026		A		628,743		(2)	04/02/2036	Ordinary Shares	628,743	$0	628,743	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

2. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

Remarks:

	/s/ Elimara Brunetto as Attorney-in- Fact for Jurgi Camblong	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did SOPHiA GENETICS (SOPH) CEO Jurgi Camblong receive?

Jurgi Camblong received two equity grants: 628,743 share options with a $5.040 exercise price and 431,211 restricted stock units (RSUs). Each RSU represents one ordinary share, aligning his compensation with SOPHiA GENETICS’ long-term share performance over a multi-year vesting schedule.

How do the new RSUs for SOPHiA GENETICS (SOPH) CEO vest over time?

The 431,211 RSUs vest gradually between 2027 and 2030. Twenty-five percent vest on April 2, 2027, and the remaining 75% vest in equal quarterly installments through April 2, 2030, conditioned on Jurgi Camblong’s continued service with SOPHiA GENETICS.

What are the terms of the SOPHiA GENETICS (SOPH) CEO’s new stock options?

The CEO was granted 628,743 share options with a $5.040 exercise price per ordinary share. These options vest 25% on April 2, 2027, then in equal monthly installments through April 2, 2030, and have an expiration date of April 2, 2036, if not exercised earlier.

Are the SOPHiA GENETICS (SOPH) CEO’s recent Form 4 transactions open-market buys or sales?

The reported transactions are not open-market trades. They are equity compensation awards: a grant of stock options and a grant of RSUs. Both are classified as “grant, award, or other acquisition” and carry a transaction price of $0.0000, reflecting their compensatory nature.

What conditions apply to vesting of SOPHiA GENETICS (SOPH) CEO RSUs and options?

Both RSUs and options require continued service with the company. RSUs vest quarterly and options monthly after initial cliffs in 2027, finishing by 2030. If Jurgi Camblong’s service ends before scheduled dates, unvested portions may not be earned under the plan terms.

Under which plan were the SOPHiA GENETICS (SOPH) CEO’s RSUs granted?

The RSUs were granted under SOPHiA GENETICS’ 2021 Equity Incentive Plan. Each RSU is a contingent right to receive one ordinary share, with vesting from April 2, 2027, through April 2, 2030, provided Jurgi Camblong remains in service with the company throughout vesting.